Introduction content: cursory refresher and review of HR+ ABC Epidemiology: Statistics and survival Pathophysiology and clinical features

Management of HR+ ABC Goals of therapy Locally advanced disease Treatment considerations for metastatic disease ·       HER2-negative: ·       Endocrine therapy & targeted agents ·       Estrogen depletion ·       Selective estrogen receptor (ER) modulators or ER down-regulators ·       Targeted therapy ·       Cyclin-dependent kinase (CDK) 4/6 inhibitors ·       Mechanistic target of rapamycin (mTOR) inhibition ·       Tumor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-targeting agents for those with mutations ·       Consideration of chemotherapy for: Patients with rapidly progressive, symptomatic disease or visceral metastases with end-organ dysfunction ·       HER2-positive: HER2-directed agent plus chemotherapy or endocrine therapy ·       Treatment resistance & later-line therapy ·       Additional considerations: Pre-menopausal women, men, BRCA mutation carriers ·       Emerging therapies ·       Novel selective estrogen receptor (ER) down-regulators (SERDs) ·       Selective ER alpha covalent antagonism ·       Additional PIK3CA-targeting agents ·       Type 1, 2, 3, and/or 4 fibroblast growth factor receptor antagonists Treatment challenges and barriers to care [Learning objective #4] Patient cases

By the end of the session the participant will be able to:

• Describe guideline-recommended therapy for HR+ ABC.
• Recall first- and later-line pharmacotherapies for HR+ ABC.
• Discuss investigational therapies for HR+ ABC, their mechanisms of action, and their anticipated place in therapy.
• List the challenges and barriers to care associated with treating patients with HR+ ABC.
• Formulate a treatment plan for a patient with HR+ ABC.

ACCME Activity #201813468

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure:

Anees B. Chagpar, MD, Professor, Department of Surgery, Yale University School of Medicine, is on the board of directors for Protean Biodiagnostics; received royalties from UpToDate, and has received financial compensation for consulting work/speaker from Sanofi Aventis, Novartis, Guardant Health, Puma Diagnostics, Lumicell, and Athenex.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will not discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by educational grants from Sanofi and Eisai.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version